Zhejiang Jiuzhou Pharmaceutical (603456.SS) Earnings Analysis
Zhejiang Jiuzhou Pharmaceutical (603456.SS) has no confirmed upcoming earnings date. Last quarter (2026-04-24) it missed with EPS 0.19 CNY vs 0.32 CNY est (-40.6%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E 20.24.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 603456.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 603456.SS. This page updates as the calendar is published.
603456.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-24 | 0.19 CNY | 0.32 CNY | -40.6% | Miss |
| 2026-04-23 | -0.02 CNY | 0.26 CNY | -107.7% | Miss |
| 2025-04-14 | 0.28 CNY | 0.19 CNY | +47.4% | Beat |
| 2024-10-24 | 0.1736 CNY | n/a | n/a | n/a |
| 2024-08-26 | 0.2652 CNY | n/a | n/a | n/a |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
603456.SS valuation and analyst view
| Trailing P/E | 20.24 |
|---|---|
| Trailing EPS | 0.71983 CNY |
| Price / book | 1.51 |
| Dividend yield | 2.03% |
| Market cap | 13.38B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Zhejiang Jiuzhou Pharmaceutical (603456.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 603456.SS. This page updates as the calendar is published.
Did 603456.SS beat earnings last quarter?
In its 2026-04-24 report, 603456.SS posted EPS of 0.19 CNY versus a 0.32 CNY estimate — a miss of 40.6%.
What is 603456.SS's earnings track record?
Over the last 3 reported quarters with consensus data, 603456.SS beat estimates 1 times (33%).
What is 603456.SS's current P/E ratio and EPS?
603456.SS trades at a trailing P/E of 20.24 on trailing EPS of 0.7198300464510404 CNY.
What do analysts rate 603456.SS?
603456.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.